BioSpace News Archive

Pfizer Inc. reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS and reaffirmed all other components of its 2020 financial guidance, which continues to reflect actual and anticipated business impacts from the novel coronavirus disease of 2019 pandemic.

Santen Pharmaceutical Co., Ltd and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc, announced an exclusive license agreement covering the development, registration, and commercialization rights in Japan, China, and other Asian countries as well as EMEA countries

Sales of $520 million declined 13% as reported and 12% in constant currency

LabCorp announced results for the second quarter ended June 30, 2020.

resTORbio resTORbio, Inc. announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1, as compared to placebo for COVID-19 post-exposure prophylaxis in older adults.

Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s second quarter 2020 financial results will be released on Monday, August 10, 2020.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 4:30 p.m. ET to discuss operational and financial results for the second quarter ended June 30, 2020.

Plus Therapeutics, Inc. announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.

Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020 at 8:30 a.m.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced that Sol-Gel has been informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021.